Vera CEO sells 46,250 shares in 10b5-1 plan
Vera Therapeutics, Inc. director and CEO Marshall Fordyce reported open-market sales of an aggregate 46,250 shares of Class A common stock on July 7, 2026.
Rhea-AI Filing Summary
Vera Therapeutics, Inc. director and CEO Marshall Fordyce reported open-market sales of an aggregate 46,250 shares of Class A common stock on July 7, 2026. The shares were sold at weighted-average prices reflecting trade ranges from $40.39 to $43.97 per share.
The filing notes the sales were made under a written trading plan adopted on January 9, 2026 that meets Rule 10b5-1(c) requirements. Following these transactions, Fordyce holds 151,994 shares directly, plus 99,081 shares held by a trust and 122,949 shares held by a GRAT, both reported as indirect ownership.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 46,250 shares
Net Sell
6 txns
Insider
Fordyce Marshall
Role
PRESIDENT AND CEO
Sold
46,250 shs ($1.96M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Class A Common Stock | 1,000 | $40.7762 | $41K |
| Sale | Class A Common Stock | 32,550 | $42.0736 | $1.37M |
| Sale | Class A Common Stock | 10,500 | $42.8578 | $450K |
| Sale | Class A Common Stock | 2,200 | $43.5947 | $96K |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
Holdings After Transaction:
Class A Common Stock — 151,994 shares (Direct);
Class A Common Stock — 122,949 shares (Indirect, By GRAT);
Class A Common Stock — 99,081 shares (Indirect, By Trust)
Footnotes (5)
- F1. This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
- F2. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.39 to $41.31, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F3. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.40 to $42.39, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F4. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.40 to $43.38, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F5. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.42 to $43.97, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Key Figures
Shares sold: 46,250 shares
Direct holdings after transaction: 197,244 shares
Trust holdings: 99,081 shares
+4 more
7 metrics
Shares sold
46,250 shares
Aggregate open-market sales on July 7, 2026
Direct holdings after transaction
197,244 shares
Class A common stock held directly after sales
Trust holdings
99,081 shares
Indirect ownership reported as held by trust
GRAT holdings
122,949 shares
Indirect ownership reported as held by GRAT
Sale price example
$40.7762 per share
Weighted-average price for one sale block
Sale price range (low)
$40.39 per share
Lowest price in disclosed trade ranges
Sale price range (high)
$43.97 per share
Highest price in disclosed trade ranges
Key Terms
Rule 10b5-1(c), weighted-average price, GRAT, open-market sale, +1 more
5 terms
Rule 10b5-1(c) regulatory
"written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c)"
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
weighted-average price financial
"The price reported is a weighted-average price. These shares were sold in multiple transactions"
Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.
GRAT financial
"total_shares_following_transaction 122949.0000, nature_of_ownership By GRAT"
open-market sale financial
"transaction_action open-market sale, transaction_code_description Sale in open market or private transaction"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Class A Common Stock financial
"security_title Class A Common Stock for all reported transactions"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Vera Therapeutics (VERA) report for Marshall Fordyce?
Vera Therapeutics reported that CEO Marshall Fordyce sold 46,250 shares of Class A common stock in open-market transactions. These trades occurred on July 7, 2026 under a pre-established Rule 10b5-1 trading plan and were executed at weighted-average prices in the low $40 range.
Was the Vera Therapeutics (VERA) CEO stock sale made under a Rule 10b5-1 plan?
Yes. A footnote explains the sale was made under a written trading plan adopted on January 9, 2026 that meets Rule 10b5-1(c) requirements. Such plans pre-schedule trades, helping separate routine diversification from discretionary market-timing decisions by insiders.
AI-generated analysis. How Rhea-AI works. Not financial advice.
